West German Study Group

This study tests whether adding the drug capivasertib to standard hormone therapy helps people with advanced HR+/HER2- breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib pl…

This study tests if a newer hormone therapy called elacestrant, with or without another drug, works better than standard hormone therapy to prevent breast cancer from coming back. It includes 1520 people with high-risk HR+/HER2- early breast cancer. Participants will take the ass…

This study tests two drug combinations in people with early-stage, low-risk triple-negative breast cancer. Participants receive either sacituzumab govitecan alone or with pembrolizumab before surgery. The goal is to see which approach leads to higher rates of complete tumor disap…

This study follows premenopausal women with a common type of early breast cancer to see how well different treatments work over 10 years. Participants either receive hormone therapy with ovarian suppression or chemotherapy followed by hormone therapy. The goal is to understand wh…